Peripheral Immune Modulation in Atopic Dermatitis During Dupilumab or Baricitinib Treatment Is Limited, as Assessed by Proteomic, Transcriptomic, and Torque Teno Virus Analyses
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188056 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Toke Touborg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Aarhus University Hospital, 8200 Aarhus, Denmark. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Purines, Pyrazoles, Sulfonamides. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Leo Pharma (Denmark).
Abstract (Originalsprache)
Atopic dermatitis is a common inflammatory skin disease affecting up to 10% of adults. Whether atopic dermatitis exhibits a strong systemic inflammatory signature remains debated. We characterized peripheral whole-blood alterations in adults with moderate-to-severe atopic dermatitis undergoing treatment with dupilumab or baricitinib therapy. Blood samples were collected at weeks 0, 4, and 16. Whole-blood proteins were measured using Olink, transcriptomic profiling was performed by RNA sequencing, and torque teno virus plasma levels were quantified by qPCR. During targeted atopic dermatitis therapy with dupilumab or baricitinib, clustering of samples based on gene expression levels showed no separation by time or treatment, with only a limited number of differentially expressed genes. Proteomic changes were similarly modest; however, treatment was consistently associated with decreased CCL17/TARC levels. Teno torque virus plasma load remained stable throughout therapy, indicating preserved immunocompetence. These findings suggest that the dominant inflammatory processes in atopic dermatitis may be largely tissue-restricted, supporting the use of peripheral biomarkers for pragmatic monitoring rather than mechanistic discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Aarhus University Hospital, 8200 Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, 8200 Aarhus, Denmark.
- Department of Immunology and Microbiology, University of Copenhagen, 1165 Copenhagen, Denmark.
- LEO Pharma, 2750 Ballerup, Denmark.
- Department of Clinical Immunology, Aarhus University Hospital, 8200 Aarhus, Denmark.
ORCID-Profile: Toke Touborg, Anne Sofie Frølunde, Thomas Litman, Pernille Koefoed-Nielsen, Mette Deleuran
Förderung
- Leo Pharma (Denmark)
Zitieren
APA
Touborg, T., Frølunde, A. S., Litman, T., Berg, R., Koefoed-Nielsen, P., Deleuran, M., Johansen, C., & Vestergaard, C. (2026). Peripheral Immune Modulation in Atopic Dermatitis During Dupilumab or Baricitinib Treatment Is Limited, as Assessed by Proteomic, Transcriptomic, and Torque Teno Virus Analyses. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188056
Vancouver
Touborg T, Frølunde AS, Litman T, Berg R, Koefoed-Nielsen P, Deleuran M, et al. Peripheral Immune Modulation in Atopic Dermatitis During Dupilumab or Baricitinib Treatment Is Limited, as Assessed by Proteomic, Transcriptomic, and Torque Teno Virus Analyses. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188056
BibTeX
@article{Touborg2026,
author = {Touborg, Toke and Frølunde, Anne Sofie and Litman, Thomas and Berg, Randi and Koefoed-Nielsen, Pernille and Deleuran, Mette and Johansen, Claus and Vestergaard, Christian},
title = {Peripheral Immune Modulation in Atopic Dermatitis During Dupilumab or Baricitinib Treatment Is Limited, as Assessed by Proteomic, Transcriptomic, and Torque Teno Virus Analyses},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188056}
}
EUVIMED